Clearside Biomedical Inc (CLSD) Shares Gap Up to $6.78
Clearside Biomedical Inc (NASDAQ:CLSD) gapped up before the market opened on Wednesday . The stock had previously closed at $6.66, but opened at $6.78. Clearside Biomedical shares last traded at $7.04, with a volume of 38,283 shares.
CLSD has been the subject of a number of research reports. Needham & Company LLC initiated coverage on Clearside Biomedical in a report on Tuesday, June 28th. They set a “buy” rating and a $16.00 target price for the company. Stifel Nicolaus initiated coverage on Clearside Biomedical in a report on Monday, June 27th. They issued a “buy” rating and a $13.00 price target for the company. Cowen and Company initiated coverage on Clearside Biomedical in a report on Monday, June 27th. They issued an “outperform” rating for the company. Finally, Wedbush initiated coverage on Clearside Biomedical in a report on Monday, June 27th. They issued an “outperform” rating and a $28.00 price target for the company.
The stock’s 50-day moving average price is $0.00 and its 200 day moving average price is $0.00. The company’s market capitalization is $18.63 million.
In other Clearside Biomedical news, major shareholder Venture Advisors Iv S. Hatteras acquired 414,286 shares of the company’s stock in a transaction dated Tuesday, June 7th. The shares were acquired at an average price of $7.00 per share, for a total transaction of $2,900,002.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Clearside Biomedical, Inc is a late-stage clinical biopharmaceutical company. The Company is developing drug therapies to treat blinding diseases of the eye. The Company’s product candidates are focused on diseases affecting the retina and choroid, especially diseases associated with macular edema, and are injected into the suprachoroidal space (SCS) adjacent to the choroid, using its SCS Microinjector.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.